CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer
Hanxiao Xu(Huazhong University of Science and Technology), Kongming Wu(First Affiliated Hospital of Zhengzhou University)
Cited by 82
Related Papers
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
|Molecular Cancer|2022|1.4k
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
|Molecular Cancer|2022|458
CD44 as a tumor biomarker and therapeutic target
|Experimental Hematology and Oncology|2020|405
Chimeric antigen receptor T cells: a novel therapy for solid tumors
|Journal of Hematology & Oncology|2017|306
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
|Molecular Cancer|2019|266